Eli Lilly & Co. (LLY) to Terminate Evacetrapib Development; Sees Charges
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib
October 13, 2015 8:38 AM EDTPiper Jaffray reiterated an Overweight rating on Eli Lilly (NYSE: LLY), and cut the price target to $118.00 (from $120.00), following the company's announced discontinuation of its CETP inhibitor evacetrapib. LLY's stock fell by 7.8% following the announcement.
Analyst Richard Purkiss commented, "Yesterday, LLY's stock fell by 7.8%... More
Eli Lilly (LLY) Eva Failure Increases Dependence on Sola, BMO Capital Notes
October 12, 2015 11:12 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and $90 price target on Eli Lilly (NYSE: LLY) after the company announced it would discontinue development of Evacetrapib in CV disease because of low efficacy. The firm called the news a "negative" although they... More
